TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25137427

Group type: EXPERIMENTAL
Intervention: Surgical therapy leading to remission (normal IGF-1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Persistent active acromegaly (elevated IGF-1)
Number of subjects: 42
Study: 25138249

Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 135

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 135
Study: 25138680

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 0
Study: 25139018

Group type: EXPERIMENTAL
Intervention: E7-specific CD8(+) T-cell responses
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: E6-specific CD4(+) T-cell responses
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: E6- and E7-specific CD8(+) T-cell responses
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: E7-specific CD4(+) T-cell responses
Number of subjects: 134
Study: 25139883

Group type: EXPERIMENTAL
Intervention: Obese adolescents
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lean adolescents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All subjects (obese and lean)
Number of subjects: 40
Study: 25139963

Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg or 1125 mg every 8 hours with efavirenz) plus peg-IFN alfa-2a (180 µg/week) and RBV (1000-1200 mg/day) for 12 weeks followed by peg-IFN/RBV for 32-56 weeks according to virological response at week 8
Number of subjects: 69

Group type: COMPARATOR
Intervention: Peg-IFN/RBV
Number of subjects: 69
Study: 25141098

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: African American spouses
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Non-African Americans
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Spouses
Number of subjects: 243
Study: 25141112

Group type: EXPERIMENTAL
Intervention: Ringer's acetate (1470 ml) and mannitol (15% 200 ml) during cardiopulmonary bypass
Number of subjects: 10
Study: 25141184

Group type: EXPERIMENTAL
Intervention: Targeted melanoma screening intervention
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: Referral to dermatologists
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: Providing a dermatologist's name
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: Delay before consulting a dermatologist
Number of subjects: 3923
Study: 25141237

Group type: EXPERIMENTAL
Intervention: Standard meal test in patients with T2D
Number of subjects: 50
Study: 25141820

Group type: EXPERIMENTAL
Intervention: Natural recovery from a gambling problem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resolution of a gambling problem with intermediate care intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relapses or care recourse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment through structured clinical interview and self-assessment questionnaires
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment from various gambling places and care centers
Number of subjects: 0
Study: 25142258

Group type: EXPERIMENTAL
Intervention: SGN-75 administered Q3Wk at doses escalated from 0.3 to 4.5 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SGN-75 administered weekly at doses of 0.3 or 0.6 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SGN-75 administered Q3Wk
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SGN-75 treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: SGN-75 administration Q3Wk vs. weekly dosing
Number of subjects: 58
Study: 25142320

Group type: EXPERIMENTAL
Intervention: Serum RBP4 levels in CAD patients
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Serum RBP4 levels in AMI and SA subgroups
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for CAD presence
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Correlation of variables with CAD severity
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: RBP4 concentrations and number of coronary narrowed vessels
Number of subjects: 305
Study: 25142486

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard ICS treatment)
Number of subjects: 0
Study: 25142490

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25142735

Group type: EXPERIMENTAL
Intervention: PF-04937319 (glucokinase activator) at doses of 100 mg and 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-04937319 (glucokinase activator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M1 (metabolite of PF-04937319)
Number of subjects: 0
Study: 25142770

Group type: EXPERIMENTAL
Intervention: Good sleepers (GS, n = 252) defined by PSQI < 5
Number of subjects: 500

Group type: COMPARATOR
Intervention: Poor sleepers (PS, n = 248) defined by PSQI > 5
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Short sleepers (< 6 h), normal sleepers (> 6h to < 8 h), and long sleepers (> 8 h)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 500
Study: 25143232

Group type: EXPERIMENTAL
Intervention: Multiplex method using Luminex technology to detect antibodies against 32 synthetic biotinylated peptides comprising predicted neo-antigens.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Immunized rabbits
Number of subjects: 1
Study: 25143374

Group type: EXPERIMENTAL
Intervention: 22-element multiple micronutrient powder (MNP) administered daily for 5 months
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (received nutrition, health, and hygiene education)
Number of subjects: 178
Study: 25143487

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 400 to 1200 mg (phase 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg (phase 2)
Number of subjects: 33
Study: 25144126

Group type: EXPERIMENTAL
Intervention: Fructose intake (highest quintile)
Number of subjects: 223230

Group type: COMPARATOR
Intervention: Fructose intake (lowest quintile)
Number of subjects: 223230
Study: 25144817

Group type: EXPERIMENTAL
Intervention: LTLD at 50 mg/m2 with MLHT
Number of subjects: 29
Study: 25145344

Group type: EXPERIMENTAL
Intervention: BFR regimen (bendamustine 130 mg/m2 per day for 3 days, fludarabine, and rituximab)
Number of subjects: 56
Study: 25145469

Group type: EXPERIMENTAL
Intervention: Insulin initiation support program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study: 25145775

Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 2954

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 2954

Group type: COMPARATOR
Intervention: Control (Japanese Encephalitis vaccine)
Number of subjects: 2954
Study: 25146065

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 1000
Study: 25146149

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Purging disorder (PD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 114
Study: 25147039

Group type: EXPERIMENTAL
Intervention: Directional atherectomy (DA)
Number of subjects: 800
Study: 25148012

Group type: EXPERIMENTAL
Intervention: PaCO₂ increased to 40 mm Hg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PaCO₂ increased to 50 mm Hg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PaCO₂ increased to 60 mm Hg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Return to baseline respirator settings
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous drainage of cerebrospinal fluid (CSF)
Number of subjects: 6
Study: 25148882

Group type: EXPERIMENTAL
Intervention: Postnatal plasma choline concentration in preterm infants
Number of subjects: 162

Group type: COMPARATOR
Intervention: Cord plasma choline concentration
Number of subjects: 162

Group type: COMPARATOR
Intervention: Choline concentrations in parturients
Number of subjects: 162

Group type: COMPARATOR
Intervention: Choline concentrations in non-pregnant women
Number of subjects: 162

Group type: COMPARATOR
Intervention: Prenatal glucocorticoid treatment
Number of subjects: 162
Study: 25149088

Group type: EXPERIMENTAL
Intervention: MEDI-575 (3, 6, 9, 12, or 15 mg/kg) once weekly (QW)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MEDI-575 (25 or 35 mg/kg) every 3 weeks (Q3W)
Number of subjects: 35
Study: 25149761

Group type: EXPERIMENTAL
Intervention: Candidemic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncandidemic patients (ICU) and healthy controls
Number of subjects: 0
Study: 25150172

Group type: EXPERIMENTAL
Intervention: Lymph node count ≥21
Number of subjects: 735

Group type: COMPARATOR
Intervention: Lymph node count <10
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Lymph node count
Number of subjects: 735
Study: 25150513

Group type: EXPERIMENTAL
Intervention: Inadequate pain relief (IPR) defined as an average pain score of >4 out of 10 on BPI question 5.
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Patients with IPR
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Correlation between BPI average pain question and WOMAC pain subscale
Number of subjects: 1187
Study: 25150798

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily plus rituximab 375 mg/m² intravenously (IV) weekly during cycle 1, then once per cycle until cycle 6, followed by continuous daily single-agent ibrutinib 420 mg until disease progression or until toxicities or complications precluded further treatment.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab
Number of subjects: 40
Study: 25151571

Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25152984

Group type: EXPERIMENTAL
Intervention: Promoter methylation of O6MGMT
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Promoter methylation of DAPK
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Promoter methylation of RASSF1A
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR)
Number of subjects: 53
Study: 25154677

Group type: EXPERIMENTAL
Intervention: D2 oocytes
Number of subjects: 20

Group type: COMPARATOR
Intervention: D15 oocytes
Number of subjects: 20
Study: 25154699

Group type: EXPERIMENTAL
Intervention: GOLD 1 subjects with SNP rs7671167 (FAM13A)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Emphysema-predominant GOLD 1 cluster with SNPs rs7671167 (FAM13A) and rs161976 (BICD1)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Lowest FEV1% predicted cluster with SNPs rs1980057 (HHIP) and rs1051730 (CHRNA3)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Combinations of COPD genome-wide significant SNPs
Number of subjects: 794
Study: 25154820

Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T cells
Number of subjects: 15
Study: 25155085

Group type: EXPERIMENTAL
Intervention: B-FAHF-2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 25

Group type: COMPARATOR
Intervention: FAHF-2
Number of subjects: 25
Study: 25155453

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 15
Study: 25155588

Group type: EXPERIMENTAL
Intervention: GS-9669 100 mg BID
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GS-9669 500 mg QD
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GS-9669 500 mg BID
Number of subjects: 4
Study: 25155604

Group type: EXPERIMENTAL
Intervention: 50 mg DTG once daily for 5 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg DTG once daily in combination with 700/100 mg FPV-RTV every 12 h for 10 days
Number of subjects: 12
Study: 25156560

Group type: EXPERIMENTAL
Intervention: tetanus-diphtheria-acellular pertussis vaccine
Number of subjects: 0
Study: 25157214

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg administered at least 15 min after the last dose of rocuronium
Number of subjects: 0
Study: 25159346

Group type: EXPERIMENTAL
Intervention: Radical-7 (noninvasive hemoglobin monitoring)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: iSTAT (point-of-care testing)
Number of subjects: 88

Group type: COMPARATOR
Intervention: CBC (standard laboratory complete blood count)
Number of subjects: 88
Study: 25159833

Group type: EXPERIMENTAL
Intervention: Aortic stiffness (pulse wave velocity (PWV))
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cardiac output
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Stroke volume
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cardiac index
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Spirometry, body composition, blood pressure, systemic inflammatory mediators, blood and urine biochemistry, physical and health outcomes
Number of subjects: 350
Study: 25160814

Group type: EXPERIMENTAL
Intervention: Atlas-based global shape analysis
Number of subjects: 1991
Study: 25160980

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) instrument used prospectively in 153 adult patients with EoE (72.5% male; median age, 38 years)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: PRO score (range, 0-8.52)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Highly active EoE based on endoscopic and histologic findings
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Validation study with 120 patients with EoE (60.8% male; median age, 40.5 years)
Number of subjects: 186
Study: 25162366

Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation (FMT) via nasogastric tube
Number of subjects: 4
Study: 25162446

Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescent cholangiography (IFC) with concomitant fluorescent angiography
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluorescent angiography
Number of subjects: 35
Study: 25162465

Group type: EXPERIMENTAL
Intervention: sEH inhibitor (sEHI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LXA4 (100 nM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-epi-LXA4 (100 nM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-epi-LXA4
Number of subjects: 0

Group type: COMPARATOR
Intervention: t-butyl-hydroperoxide
Number of subjects: 0
Study: 25162522

Group type: EXPERIMENTAL
Intervention: Patients with binocular glaucoma (GP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy-sighted control subjects (GC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients who passed the task (GP)
Number of subjects: 20
Study: 25162818

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 95
Study: 25163590

Group type: EXPERIMENTAL
Intervention: Phytosterols (PS) plus β-Cryptoxanthin (β-Cx)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Phytosterols (PS)
Number of subjects: 19
Study: 25163595

Group type: EXPERIMENTAL
Intervention: Neoadjuvant IMRT (median dose 50 Gy, 26-55) followed by surgery and IOERT (10-12 Gy)
Number of subjects: 27
Study: 25164021

Group type: EXPERIMENTAL
Intervention: PDC31 (1 mg/kg/h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PDC31 (0.01, 0.05, 0.15, 0.3, 0.5, 1 mg/kg/h)
Number of subjects: 24
Study: 25164234

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m(2) intravenously on day 1, and irinotecan 80 mg/m(2) on days 1 and 8, of a 21-day cycle up to 15 cycles or until disease progressed.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Docetaxel and irinotecan combination treatment.
Number of subjects: 9
Study: 25164437

Group type: EXPERIMENTAL
Intervention: Erlotinib-based 1st-line regimen
Number of subjects: 281
Study: 25164560

Group type: EXPERIMENTAL
Intervention: M probe (LSM1)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: M probe re-evaluation by experienced operators (LSM2)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: XL probe (LSMXL)
Number of subjects: 868
Study: 25164945

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy added to a standard heart failure regimen
Number of subjects: 12
Study: 25165055

Group type: EXPERIMENTAL
Intervention: SAGB (Swedish Adjustable Gastric Band)
Number of subjects: 29
Study: 25165428

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone administered every other day for up to fourteen days.
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 195
Study: 25166023

Group type: EXPERIMENTAL
Intervention: Canagliflozin 30, 100, 200, or 400 mg once daily or 300 mg twice daily, or placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 25166484

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride (HCL), 200 to 300 mg/d, twice-daily immediate-release
Number of subjects: 4
Study: 25167069

Group type: EXPERIMENTAL
Intervention: Intervention: Detoxification treatment for alcohol use disorder
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control: Not applicable
Number of subjects: 164
Study: 25167204

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Formula feeding (FF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF) for at least 1 year
Number of subjects: 56
Study: 25167216

Group type: EXPERIMENTAL
Intervention: Anti-TNFα therapy (adalimumab)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Anti-IL-6R therapy (tocilizumab)
Number of subjects: 198
Study: 25168219

Group type: EXPERIMENTAL
Intervention: Iso-fludelone (KOS-1803)
Number of subjects: 0
Study: 25168842

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 120
Study: 25169593

Group type: EXPERIMENTAL
Intervention: Y-shaped Medtronic bifurcation-dedicated stent (BDS)
Number of subjects: 45
Study: 25169854

Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg over 40 min)
Number of subjects: 133
Study: 25169950

Group type: EXPERIMENTAL
Intervention: Copeptin levels
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: ABCD2 score with copeptin
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: ABCD3-I score with copeptin
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Risk reclassification based on copeptin
Number of subjects: 302
Study: 25170013

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) and Dasatinib (70 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 35
Study: 25170123

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL1/ABL ≤10% at 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Imatinib treatment with BCR-ABL1/ABL >10% at 3 months
Number of subjects: 40
Study: 25170245

Group type: EXPERIMENTAL
Intervention: TRAV/TIM-FC (travoprost 0.004%/timolol 0.5%) administered once daily at 8 pm for 4-6 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: TRAV/TIM-FC
Number of subjects: 49
Study: 25171955

Group type: EXPERIMENTAL
Intervention: Prescription opioid users
Number of subjects: 529

Group type: COMPARATOR
Intervention: Heroin users
Number of subjects: 529
Study: 25173047

Group type: EXPERIMENTAL
Intervention: EPHX2 287Gln variant
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: EPHX2 Arg287Gln genotype
Number of subjects: 85

Group type: COMPARATOR
Intervention: EPHX2 287Gln carriers
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Total EETs
Number of subjects: 85
Study: 25173458

Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib (sorafenib at 400 mg/bid, TACE with lipiodol, 50 mg doxorubicin, and PVA particles repeated q6w)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib
Number of subjects: 43
Study: 25173754

Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 728
Study: 25174587

Group type: EXPERIMENTAL
Intervention: CD33-directed chimeric antigen receptor-modified T cells (CART-33)
Number of subjects: 1
Study: 25174996

Group type: EXPERIMENTAL
Intervention: Quetiapine immediate release (IR)
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Quetiapine extended release (XR)
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Quetiapine IR and XR (combined analysis)
Number of subjects: 1230
Study: 25175077

Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on past caries experience in adult patients
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on use of fluorides in adult patients
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on oral hygiene in pediatric patients
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Caries risk assessment (CRA) decision based on use of fluorides in pediatric patients
Number of subjects: 189
Study: 25175512

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25175864

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innate immune pattern-recognition receptor TLR4
Number of subjects: 0
Study: 25178675

Group type: EXPERIMENTAL
Intervention: Advagraf®-based immunosuppression
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (MELD-score ≤20)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (MELD-score >20)
Number of subjects: 50
Study: 25179289

Group type: EXPERIMENTAL
Intervention: Decision aids (shared decision making tools)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Control (no decision aids)
Number of subjects: 775
Study: 25179634

Group type: EXPERIMENTAL
Intervention: sSOAIC (standard selective ophthalmic artery infusion chemotherapy)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: bSOAIC (balloon-assisted selective ophthalmic artery infusion chemotherapy)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Temporary balloon occlusion (TBO) of the external carotid artery (ECA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Verapamil infusion into the OA and internal carotid artery
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overall procedure
Number of subjects: 17
Study: 25180155

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAK1/2 inhibitor)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 1